Drug Trial Radar · NCT04950764
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Last checked: Nov 20, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 16, 2021
Primary completion
Feb 24, 2025
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Participants with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Conditions
- Primary Biliary Cholangitis
- Compensated Cirrhosis
- Hepatic Impairment
Interventions
SeladelparDrug
Tablets Administered Orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
- Part A: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
- Part A: PK Parameter: AUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
- Part A: PK Parameter: AUC0-inf of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
- Part B: PK Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
- Part B: PK Parameter: Cmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
- Part B: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
- Part B: PK Parameter: Tmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
- Part B: PK Parameter: AUC0-24 of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
- Part B: PK Parameter: AUC0-tau of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
- Part B: PK Parameter: RCmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
- Part B: PK Parameter: RAUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
- Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEsTime frame: Part A: Up to Week 5; Part B: Up to Week 8
- Percentage of Participants Who Experienced Any Grade and Grade 3 or 4 TEAEsTime frame: Part A: Up to Week 5; Part B: Up to Week 8
- Percentage of Participants Who Experienced TEAEs of Special InterestTime frame: Part A: Up to Week 5; Part B: Up to Week 8
- Percentage of Participants With Clinically Significant Changes in Vital SignsTime frame: Part A: Up to Day 4; Part B: Up to Day 31
- Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) FindingsTime frame: Part A: Up to Day 4; Part B: Up to Day 28
- Percentage of Participants Who Experienced Laboratory AbnormalitiesTime frame: Part A: Up to Day 4; Part B: Up to Day 31
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Arizona Liver Health
Chandler, Arizona
University of California Davis
Sacramento, California
University of Colorado Anschutz
Aurora, Colorado
Mercy Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health System
Novi, Michigan
Southern Therapy and Advanced Research LLC
Jackson, Mississippi
Weill Medical College of Cornell University
New York, New York
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas
American Research Corporation
San Antonio, Texas
Pinnacle Clinical Research- SA
San Antonio, Texas
Pusan National University Hospital
Busan, South Korea
Inje University Busan Paik Hospital
Busan, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Hospital General Universitario Gregorio Maran
Madrid, Spain
NIHR BRC Centre for Liver and Gastrointestinal Research Birmingham
Birmingham, United Kingdom
The Royal Free London NHS Foundation Trust
London, United Kingdom
Kings College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.